Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Key Inclusion Criteria: * Pathologically or cytologically documented advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available, or the patient refuses standard therapy. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Men or women at least 18 years of age * Adequate hematologic, cardiac, renal, hepatic, metabolic, and coagulation function Key Exclusion Criteria: * Presence of untreated or symptomatic brain metastasis. * Presence of ascites or pleural effusion requiring chronic medical intervention. * Uncontrolled hypertension * Concurrent or previous (within 1 week of study day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) or low dose,low molecular weight heparin for prophylaxis against central venous catheter thrombosis. * Recent major surgical procedure or not yet recovered from major surgery * Recent participation in clinical drug trials. * Participation in other investigational procedures. * Unresolved toxicities from prior anti-cancer therapy * Patient who is pregnant (e.g. positive human choriogonadotropin \[HCG\] test) or nursing.